Foundational Neurotoxin
Learn the science, assessment, preparation and follow-up behind an individualized neurotoxin treatment. Put the clinical skills into practice with your instructor at the live workshop.
FACULTY REVIEW EDITION · 2026.10Use de-identified learning notes only. Demonstrations and procedural practice take place in the live instructor-led workshop. Complete the interactive lesson checks and final assessment in your classroom to save online progress.
Your study plan
The clinical care pathway
Learning goal: Distinguish an educational achievement from the permissions and clinical arrangements needed to treat.
Build the care pathway
Begin with the person seeking treatment, the treating clinician and the clinician responsible for assessment and prescribing. Identify who can authorize care, who will administer it, who is available for questions, and who will manage follow-up. A shared medical director does not remove the need for a patient-specific assessment and a clear chain of responsibility.
Use documents deliberately
Before the clinical day, locate the current protocol, applicable product label, assessment record, consent, emergency contacts and documentation system. Check revision dates and signatures. A template bearing another practice or physician name needs reconciliation; it is not evidence of an active appointment.
Know what completion records
This written course records theoretical learning. Live faculty separately observe communication, preparation and clinical performance. A course completion certificate records those defined achievements; professional scope, prescribing authority and facility requirements come from the applicable governing bodies.
Key takeaways
- Identify the authorized prescriber and supervising clinician.
- Use current, approved documents for the actual practice.
- Keep online and observed clinical completion separate.
Case exercise
A learner passes the online exam and is asked to treat a model before an instructor has reviewed eligibility or the clinical plan.
What must happen before participation?Knowledge check
What does a passed online assessment establish?
□ A. Independent authority to inject
□ B. Completion of the defined knowledge assessment
□ C. Permission to prescribe
□ D. Clinical competency in every facial region
References: Arkansas State Board of Nursing — laws and rules
Facial expression and muscle action
Learning goal: Connect visible movement to muscle function and baseline assessment.
Elevates the eyebrows.
Contribute to medial brow and glabellar expression.
Closes the eyelids; contributes to expression around the eye.
Observe rest and movement
Begin with relaxed photographs and then observe intentional expressions. Separate a line visible only with movement from a crease also present at rest. Ask whether the patient is lifting the brows to compensate for a heavy upper lid. Baseline posture, asymmetry and compensatory movement affect the treatment conversation.
Learn the functional groups
The frontal belly of occipitofrontalis elevates the eyebrows. Corrugator activity draws the brows medially; procerus contributes to the central glabellar expression. Orbicularis oculi closes the eyelids. These muscles interact rather than operating as isolated cosmetic targets. Reducing one action can alter the balance of another.
Document a functional baseline
Describe brow height, lid position, eye closure and asymmetry before treatment. Use the same lighting, view and expression when comparing later photographs. The muscle diagram is an orientation aid; individual depth, boundaries and vascular relationships require live anatomical teaching and assessment.
Key takeaways
- Examine at rest and in animation.
- Record asymmetry before discussing correction.
- Protect function as well as appearance.
Case exercise
A patient keeps the forehead contracted even while attempting to relax.
Why is a standard forehead plan inappropriate without further assessment?Knowledge check
Which muscle primarily elevates the eyebrows?
□ A. Orbicularis oris
□ B. Masseter
□ C. Frontal belly of occipitofrontalis
□ D. Orbicularis oculi
References: OpenStax — Muscles of the Head, Neck, and Back; BOTOX Cosmetic — manufacturer prescribing information
Neurotoxin science and product identity
Learning goal: Explain the mechanism and distinguish product-specific units, indications and evidence.
What the treatment changes
Botulinum toxin type A interferes with acetylcholine release at the neuromuscular junction, reducing activity in the affected muscle. It changes movement; it does not replace lost tissue volume. A static crease, skin laxity or skeletal change may require a different discussion about realistic outcomes.
Read the exact label
Identify the brand, nonproprietary name, vial strength and intended indication. BOTOX Cosmetic, XEOMIN and DAXXIFY have their own assays and prescribing information. Potency units are product-specific. Do not transfer a dose or create a fixed conversion rule between brands from a price-per-unit comparison.
Discuss timing honestly
Onset, duration and retreatment decisions depend on the product, indication and patient response. Trial averages do not promise an individual result. Review previous products and treatment dates, and agree on a follow-up plan that allows a response to be assessed before considering further treatment.
Compare labeled uses, not unit prices
The reference table identifies selected U.S. products and cosmetic indications. Each listed use concerns temporary improvement of moderate to severe lines or bands as specified in the label. Age criteria and required treatment combinations matter. A neck indication for BOTOX Cosmetic does not establish a neck indication for another brand. Read the full label before planning; this table does not specify dose, placement, equivalence or duration.
Know the product. Read its label.
Selected products reviewed October 23, 2026. Uses below concern temporary improvement of moderate to severe lines or bands. Check the full current label for patient selection, treatment combinations and all warnings.
| Brand / label | Nonproprietary name | Labeled cosmetic areas / population |
|---|---|---|
| BOTOX Cosmetic ↗ | onabotulinumtoxinA | Glabellar lines, lateral canthal lines, forehead lines and platysma bands in adults. |
| DYSPORT ↗ | abobotulinumtoxinA | Glabellar lines in adults younger than 65. |
| XEOMIN ↗ | incobotulinumtoxinA | Upper facial lines: glabellar, horizontal forehead and lateral canthal lines in adults. |
| JEUVEAU ↗ | prabotulinumtoxinA-xvfs | Glabellar lines in adults. |
| DAXXIFY ↗ | daxibotulinumtoxinA-lanm | Glabellar lines in adults. |
| LETYBO ↗ | letibotulinumtoxinA-wlbg | Glabellar lines in adults. |
Potency units are product-specific and cannot be converted using this table. Therapeutic indications are outside this comparison. Approval of an area for one product does not extend that approval to another product.
Key takeaways
- Product identity comes before any calculation.
- Movement reduction is different from volume restoration.
- Use the current label, not a generic toxin recipe.
Case exercise
A patient requests the same number of units of a different toxin because the unit price is lower.
How would you explain the problem?Knowledge check
A switch between toxin brands should use:
□ A. A universal 1:1 conversion
□ B. The cheapest unit count
□ C. The previous volume alone
□ D. A product-specific clinical plan
Additional practice 1
Which conclusion is supported by the product reference table?
□ A. Approval in one brand transfers to the other brands
□ B. Every brand has an approved forehead indication
□ C. The exact product, patient population and labeled use must be checked
□ D. The table provides equivalent doses
References: BOTOX Cosmetic — manufacturer prescribing information; XEOMIN — FDA prescribing information, June 2026; DAXXIFY — prescribing information on DailyMed; DYSPORT — manufacturer prescribing information; JEUVEAU — prescribing information on DailyMed; LETYBO — FDA prescribing information
Consultation, consent and photography
Learning goal: Build a consultation that connects goals, relevant history and an agreed plan.
Ask before planning
Invite the patient to explain what bothers them and what a worthwhile result would mean. Review previous toxin and filler, treatment dates, response and complications. Obtain relevant medical history, allergies, medications, pregnancy or breastfeeding status, neuromuscular symptoms, swallowing problems and infection at the proposed treatment area. Have the prescriber resolve suitability questions.
Differentiate exclusions and precautions
Product labeling distinguishes contraindications from warnings, precautions and evidence gaps. A history of hypersensitivity to the product or infection at the site has different implications from a condition requiring individualized assessment. Do not turn a generic checklist into an unsupported rule that every autoimmune diagnosis is either safe or prohibited.
Make consent a conversation
Explain the intended benefit, limitations, alternatives including no treatment, expected effects, meaningful risks, cost and follow-up. Check understanding in the patient’s own words. Record standardized baseline photographs with appropriate consent; marketing permission is a separate choice from clinical documentation.
Make the allergy review product-specific
Ask what substance caused a previous reaction and what actually happened. DYSPORT specifically lists hypersensitivity to cow’s milk protein as a contraindication because trace amounts may be present. Review the ingredients and contraindications of the intended product with the prescriber; do not assume all toxin formulations share the same allergy profile. Record unresolved allergy questions before considering an alternative.
Key takeaways
- Clarify the patient’s own goals.
- Resolve history concerns before treatment.
- Document consent and baseline appearance.
Case exercise
A patient wants every facial line gone before an event tomorrow.
What should the consultation address?Knowledge check
Which consent approach is strongest?
□ A. A signature without discussion
□ B. A guarantee of a perfect result
□ C. Benefits, risks, alternatives and teach-back
□ D. A social-media testimonial
Additional practice 1
A patient reports a cow’s milk protein allergy before a proposed DYSPORT treatment. What is the appropriate response?
□ A. Proceed if the patient signs a waiver
□ B. Recognize the labeled contraindication and return the treatment decision to the prescriber
□ C. Assume every toxin has identical ingredients
□ D. Reduce the planned amount without review
References: BOTOX Cosmetic — manufacturer prescribing information; DAXXIFY — prescribing information on DailyMed; DYSPORT — manufacturer prescribing information; JEUVEAU — prescribing information on DailyMed
Asepsis, storage and preparation checks
Learning goal: Recognize the controls required before a product reaches the treatment tray.
Separate clean preparation from used equipment
Prepare medication in a designated clean area. Perform hand hygiene and use appropriate protective equipment. A new sterile needle and syringe are needed for each patient and access as required; replacing a needle does not make a used syringe clean. Keep used equipment away from stock and clean surfaces.
Verify the product
Check authorized source, integrity, expiration and lot information. Read the exact product’s storage and preparation directions, including diluent, temperature, handling and permitted time after reconstitution. Do not apply a blanket freezing rule or a 30-day storage rule to every toxin. Document preparation time and concentration where required.
Protect single-dose handling
Follow single-dose labeling and disposal requirements. Do not pool leftovers or share a single-dose vial between patients. If sterility, identity or storage is uncertain, quarantine the product and resolve the uncertainty before use. The live workshop includes observed setup and preparation with the instructor.
Resolve sourcing concerns before use
A familiar logo or a low price does not establish authenticity. Verify an authorized supply chain and keep purchase, lot and storage records available for traceability. Set aside stock with uncertain provenance or handling and contact the responsible clinician and supplier. If a patient may already have received a suspect product, prioritize clinical assessment and preserve the relevant records for investigation.
Key takeaways
- Check the exact label at preparation.
- Discard contaminated or uncertain supplies.
- Never reuse a syringe between patients.
Case exercise
A prepared vial has no preparation time or concentration recorded.
What should happen next?Knowledge check
Changing the needle on a used syringe:
□ A. Does not make that syringe safe for another patient
□ B. Sterilizes the syringe
□ C. Allows entry into shared stock
□ D. Makes single-dose sharing acceptable
References: CDC — Preventing Unsafe Injection Practices; CDC — Hand Hygiene for Healthcare Workers; BOTOX Cosmetic — manufacturer prescribing information; XEOMIN — FDA prescribing information, June 2026; FDA — Counterfeit Version of Botox Found in Multiple States
Units, milliliters and calculation checks
Learning goal: Distinguish labeled potency, concentration and syringe volume in a supervised calculation exercise.
Keep the quantities separate
A vial contains a labeled quantity of product-specific potency units. Reconstitution produces a concentration expressed as those units per milliliter. The volume withdrawn is a third quantity. A syringe marking measures a volume scale; it does not become a toxin potency unit merely because the syringe is marked in insulin units.
Work a hypothetical exercise
For arithmetic practice only, assume an instructor has supplied a prepared concentration of 40 product units/mL and a hypothetical authorized amount of 8 product units. Volume = amount ÷ concentration, so 8 ÷ 40 = 0.20 mL. Check by multiplying 0.20 mL × 40 units/mL = 8 units. This exercise does not select a product, dilution, facial site or clinical dose.
Build the independent check
Read back the product name, concentration, authorized amount, calculated volume and syringe scale. Write units on every line. Resolve disagreements with the instructor before preparation. A correct calculation cannot correct an inappropriate clinical order or the wrong product.
Key takeaways
- Write units on every calculation.
- Use amount ÷ concentration to find volume.
- Verify the order and product before the math.
Case exercise
Two labels say “8 units,” but one refers to toxin potency and the other to an insulin syringe scale.
Why can they not be treated as equivalent?Knowledge check
For a hypothetical 40 units/mL concentration, 8 product units occupy:
□ A. 0.02 mL
□ B. 0.20 mL
□ C. 2.0 mL
□ D. 8 mL
References: BOTOX Cosmetic — manufacturer prescribing information; XEOMIN — FDA prescribing information, June 2026
Expected effects, warning symptoms and follow-up
Learning goal: Differentiate routine follow-up from symptoms needing urgent assessment.
Prepare the patient for follow-up
Provide written, product- and clinic-specific aftercare, contact details and an agreed review plan. Explain that the patient should report unexpected changes rather than waiting for a routine review. Document baseline findings and the actual treatment so the follow-up clinician can interpret a change.
Assess unwanted local effects
Bruising, headache, eyelid or brow changes, dryness or unwanted weakness merit assessment appropriate to their severity. Establish onset, progression, affected function and associated symptoms. Do not guarantee that every asymmetry resolves within a fixed number of days or offer further treatment without an assessment.
Recognize urgent systemic symptoms
Breathing or swallowing difficulty, speech change or generalized weakness after toxin warrants immediate medical assessment; severe or rapidly progressing symptoms require emergency services. Contact the responsible clinician while arranging appropriate care. A message in a routine inbox is not an emergency response pathway.
Respond to a suspected preparation or dosing error
Stop further administration and immediately notify the responsible clinician if the wrong product, concentration or amount may have been given. Arrange prompt medical evaluation even if the patient currently feels well; symptoms can be delayed. Reconstruct the actual product, amount, preparation and administration time, and preserve the records. The evaluating clinician determines monitoring and further care. Do not substitute an uneventful first hour for a clinical plan.
Know the botulism consultation pathway
If botulism is suspected, the treating clinician should urgently contact the state public health department for expert consultation and possible antitoxin access while arranging appropriate medical care. CDC advises against waiting for laboratory confirmation when clinical consultation supports treatment. Antitoxin does not reverse established paralysis. Breathing or swallowing difficulty needs immediate medical attention, with emergency services for severe or progressing symptoms.
Report without delaying care
After immediate care is underway, document the event, clinical handoff and follow-up owner. Suspected medication adverse events, including those involving a possibly counterfeit product, can be reported to FDA MedWatch and the manufacturer. An internal incident report serves a different purpose from an external safety report; preserve traceability for both.
Key takeaways
- Give an actionable contact plan.
- Evaluate function, not appearance alone.
- Escalate systemic warning symptoms immediately.
Case exercise
A patient calls after treatment describing difficulty swallowing and new generalized weakness.
Is this a routine touch-up question?Knowledge check
New breathing difficulty after toxin requires:
□ A. Waiting for a two-week photo
□ B. Only a cosmetic review
□ C. Immediate medical evaluation
□ D. A larger dose next time
Additional practice 1
A concentration error is discovered after treatment, but the patient has no symptoms. What should happen next?
□ A. Close the incident because there are no symptoms
□ B. Wait for the patient’s routine follow-up
□ C. Give another product to balance the result
□ D. Stop further treatment, notify the clinician and arrange prompt medical evaluation
References: BOTOX Cosmetic — manufacturer prescribing information; DAXXIFY — prescribing information on DailyMed; CDC — Clinical Overview of Botulism; FDA — Counterfeit Version of Botox Found in Multiple States
Prepare for your live neurotoxin workshop
Learning goal: Bring a structured case presentation and readiness checklist to the instructor.
Present the case before the procedure
Use a consistent sequence: the patient’s goal, relevant history, baseline function and movement, product-specific rationale, alternatives, consent, authorized plan and follow-up. Separate what you observed from what you inferred. Ask the instructor to challenge your assumptions before any treatment begins.
Demonstrate the complete workflow
The live session includes anatomical identification, patient-specific planning, preparation, dose and volume checks, technique demonstration, supervised participation and documentation. Injection location, depth, angle and delivery are taught and assessed in person within the approved protocol. Observing a demonstration is different from independently performing a skill.
Use feedback to plan the next case
Record what was completed, what required prompting and what needs more practice. Faculty should document observed performance rather than signing every box simply because the learner attended. Take a de-identified learning question into mentorship, while keeping patient records in the clinical record system.
Key takeaways
- Bring the completed study record.
- Expect direct observation and feedback.
- Plan remediation for any unmet skill.
Case exercise
A learner answers the exam correctly but cannot explain a concentration check at the tray.
How should faculty document the result?Knowledge check
Clinical sign-off should be based on:
□ A. Attendance alone
□ B. Online score alone
□ C. Number of products purchased
□ D. Observed performance against defined criteria
References: CDC — Preventing Unsafe Injection Practices; Arkansas State Board of Nursing — laws and rules
Discussion & answer key
Complete your responses first, then compare your reasoning.
1. The clinical care pathway
Knowledge check: B. It documents the assessed knowledge. Clinical skill and practice authority require separate verification.
Case discussion: Pause clinical participation. Confirm eligibility, assessment, consent, the authorized plan and instructor readiness. An online score alone does not establish clinical competence.
2. Facial expression and muscle action
Knowledge check: C. Frontalis elevates the brows; the surrounding muscles influence the overall balance.
Case discussion: Persistent contraction may be compensatory. Assess lid and brow position, functional concerns and goals with the instructor before proposing reduction of activity.
3. Neurotoxin science and product identity
Knowledge check: D. The units and labeling are specific to each product.
Case discussion: Different products do not share interchangeable potency units. The prescriber develops a product-specific plan; price comparisons should not dictate dose equivalence.
Additional practice 1: C. The table compares product identity and labeled cosmetic uses. It cannot establish interchangeable units or authorize a treatment plan.
4. Consultation, consent and photography
Knowledge check: C. Consent includes a two-way discussion and documented understanding.
Case discussion: Discuss delayed onset, the possibility of bruising and limits of treatment. Do not promise a next-day result. Deferring an elective procedure may be the most appropriate plan.
Additional practice 1: B. Cow’s milk protein hypersensitivity is a labeled DYSPORT contraindication. A waiver or a smaller amount does not remove it. Any alternative requires its own assessment.
5. Asepsis, storage and preparation checks
Knowledge check: A. The syringe remains contaminated after use.
Case discussion: Set it aside and reconcile the record with the responsible clinician. Do not guess the concentration or assume another product’s storage window applies.
6. Units, milliliters and calculation checks
Knowledge check: B. 8 units divided by 40 units/mL equals 0.20 mL.
Case discussion: They describe different quantities. Confirm the product concentration and volume rather than assuming the labels mean the same thing.
7. Expected effects, warning symptoms and follow-up
Knowledge check: C. Potential systemic toxin effects require urgent medical assessment.
Case discussion: No. Arrange immediate medical evaluation and activate emergency services when severe or progressing. Notify the responsible clinician and document the handoff.
Additional practice 1: D. Symptoms may be delayed. A suspected error requires timely evaluation and a clinician-directed monitoring plan, with accurate product and administration records.
8. Prepare for your live neurotoxin workshop
Knowledge check: D. Faculty verify clinical performance separately from the knowledge assessment.
Case discussion: Record the knowledge result and the specific practical gap separately. Provide supervised remediation and reassess the skill before clinical completion.
Reference reading
Arkansas State Board of Nursing — laws and rules
https://healthy.arkansas.gov/boards-commissions/boards/nursing-arkansas-state-board/laws-rules/
OpenStax — Muscles of the Head, Neck, and Back
https://openstax.org/books/anatomy-and-physiology-2e/pages/11-3-axial-muscles-of-the-head-neck-and-back
BOTOX Cosmetic — manufacturer prescribing information
https://www.rxabbvie.com/pdf/botox-cosmetic_pi.pdf
XEOMIN — FDA prescribing information, June 2026
https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/125360s108lbl.pdf
DAXXIFY — prescribing information on DailyMed
https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3aaa6e14-a3f7-4fb2-b9f9-d3a9c3ae1f74
DYSPORT — manufacturer prescribing information
https://www.dysportusa.com/PI
JEUVEAU — prescribing information on DailyMed
https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=17a914c1-e54b-4b50-965d-b0fd9111bba4
LETYBO — FDA prescribing information
https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/761225s000lbl.pdf
CDC — Preventing Unsafe Injection Practices
https://www.cdc.gov/injection-safety/hcp/clinical-safety/index.html
CDC — Hand Hygiene for Healthcare Workers
https://www.cdc.gov/clean-hands/hcp/clinical-safety/index.html
FDA — Counterfeit Version of Botox Found in Multiple States
https://www.fda.gov/drugs/drug-alerts-and-statements/counterfeit-version-botox-found-multiple-states
CDC — Clinical Overview of Botulism
https://www.cdc.gov/botulism/hcp/clinical-overview/index.html